GCI Health To Promote Botox for Migraines

Allergan has selected GCI Health to support the launch of Botox for use in the preventive treatment of chronic migraine in adults.

Botox was approved by the FDA on October 15 for use in preventing migraines in patients who suffer from headaches that last four or more hours during 15 or more days in a month. According to the press release announcing the relationship, this is the “sixth therapeutic indication for the product” since 1989.

“Botox, with current annual sales of $1.4 billion, could eventually capture $600 million or more in additional annual sales from the migraine indication, according to analysts,” Reuters reports.

While the financial results have made it a favorite on Wall Street, the story continues, Allergan agreed to plead guilty last month and pay $600 million to resolve federal accusations about Botox marketing practices.

“The Justice Department accused Allergan of paying kickbacks to doctors to prescribe Botox for unapproved uses — such as treating headaches, pain and juvenile cerebral palsy — and teaching doctors how to bill for such ‘off-label’ uses,” the Reuters story said.

Launch a social media campaign that will build your brand and deliver results in our online Social Media Marketing Boot Camp starting June 7. Speakers include Abigail Cusick (Bravo Digital), Gregory Galant (Sawhorse Media), Alex Leo (Thomson Reuters Digital), Jim Tobin (Ignite Social Media), and many more. Read the reviews.